UY33978A - Piridinonas bicíclicas nuevas. - Google Patents

Piridinonas bicíclicas nuevas.

Info

Publication number
UY33978A
UY33978A UY0001033978A UY33978A UY33978A UY 33978 A UY33978 A UY 33978A UY 0001033978 A UY0001033978 A UY 0001033978A UY 33978 A UY33978 A UY 33978A UY 33978 A UY33978 A UY 33978A
Authority
UY
Uruguay
Prior art keywords
new bicyclic
pyridinones
bicyclic pyridinones
new
página
Prior art date
Application number
UY0001033978A
Other languages
English (en)
Inventor
Subramanyam Chakrapani
Christopher William Am Ende
Benjamin Adam Fish
Michael Eric Green
Douglas Scott Johnson
Patrick Bradley Mullins
Navaratnam Thayalan
Christopher John O Donnell
Martin Youngjin Pettersson
Cory Michael Stiff
Tuan Phong Tran
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY33978A publication Critical patent/UY33978A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se divulgan compuestos y sales aceptables para uso farmacéutico de los compuestos, en donde los compuestos tienen la estructura de la Fórmula I, según lo definido en la presente. También se divulgan las correspondientes composiciones farmacéuticas, métodos de tratamiento, métodos de síntesis, e intermediarios.
UY0001033978A 2011-03-31 2012-03-28 Piridinonas bicíclicas nuevas. UY33978A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161470076P 2011-03-31 2011-03-31
US201261599022P 2012-02-15 2012-02-15

Publications (1)

Publication Number Publication Date
UY33978A true UY33978A (es) 2012-10-31

Family

ID=45937491

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033978A UY33978A (es) 2011-03-31 2012-03-28 Piridinonas bicíclicas nuevas.

Country Status (9)

Country Link
US (2) US8697673B2 (es)
EP (1) EP2691393B1 (es)
JP (1) JP5767393B2 (es)
AR (1) AR085748A1 (es)
CA (1) CA2830027C (es)
ES (1) ES2602794T3 (es)
TW (1) TW201300384A (es)
UY (1) UY33978A (es)
WO (1) WO2012131539A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ593951A (en) 2009-02-06 2013-01-25 Ortho Mcneil Janssen Pharm Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
US8835482B2 (en) 2009-05-07 2014-09-16 Janssen Pharmaceuticals, Inc. Substituted indazole and aza-indazole derivatives as gamma secretase modulators
CA2778517A1 (en) 2009-07-15 2011-01-20 Janssen Pharmaceuticals, Inc. Substituted triazole and imidazole derivatives as gamma secretase modulators
ES2512840T3 (es) 2010-01-15 2014-10-24 Janssen Pharmaceuticals, Inc. Derivados de triazol bicíclicos sustituidos novedosos como moduladores de gamma-secretasa
MX2013010970A (es) 2011-03-24 2013-10-17 Cellzome Ltd Novedosos derivados de triazolil piperazina y triazolil piperidina sustituidos como moduladores de gamma-secretasa.
CA2841102C (en) 2011-07-15 2019-08-13 Janssen Pharmaceuticals, Inc. Novel substituted indole derivatives as gamma secretase modulators
SG11201404214QA (en) 2012-02-03 2014-08-28 Teva Pharma USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
AU2013261023B2 (en) 2012-05-16 2016-11-24 Cellzome Limited Substituted 3, 4 - dihydro - 2H - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) Alzheimer's disease
UA110688C2 (uk) * 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
SG11201501874TA (en) * 2012-10-12 2015-05-28 Pharmaceutical Industries Ltd Teva Laquinimod for reducing thalamic damage in multiple sclerosis
JP2014101316A (ja) * 2012-11-20 2014-06-05 Toyobo Co Ltd ベンゾ［１，２−ｄ；４，５−ｄ’］ビスチアゾール化合物の製造方法
WO2014096212A1 (en) 2012-12-20 2014-06-26 Janssen Pharmaceutica Nv NOVEL TRICYCLIC 3,4-DIHYDRO-2H-PYRIDO[1,2-α]PYRAZINE-1,6-DIONE DERIVATIVES AS GAMMA SECRETASE MODULATORS
EP2945944B1 (en) 2013-01-17 2016-11-09 Janssen Pharmaceutica, N.V. Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
CA2925743C (en) * 2013-10-04 2018-03-06 Pfizer Inc. Novel bicyclic pyridinones as gamma-secretase modulators
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
PL3094631T3 (pl) * 2014-01-16 2019-07-31 Fmc Corporation Pochodne pirymidynyloksy-benzenu jako środki chwastobójcze
CN103787839B (zh) * 2014-01-21 2015-12-02 苏州昊帆生物科技有限公司 合成2,3,4,5,6-五氟苯酚的方法
MD20160102A2 (ro) * 2014-04-01 2017-04-30 Pfizer Inc. Cromen şi 1,1a,2,7b-tetrahidrociclopropa[c]cromen piridopirazindione ca modulatori ai gama-secretazei
CN103965093A (zh) * 2014-04-04 2014-08-06 华南理工大学 2-全氟烷基吲哚类化合物及其制备方法和应用
SG11201608674UA (en) 2014-04-29 2016-11-29 Teva Pharma Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
PE20171318A1 (es) 2015-02-03 2017-09-07 Pfizer Ciclopropabenzofuranil-piridopirazindionas novedosas
WO2016201168A1 (en) 2015-06-10 2016-12-15 Forum Pharmceuticals Inc. Oxadiazine compounds and methods of use thereof
WO2018031680A1 (en) * 2016-08-10 2018-02-15 Fronthera U.S. Pharmaceuticals Llc Novel compounds, uses and methods for their preparation
CN110256369A (zh) * 2019-07-01 2019-09-20 中国人民大学 一种制备多氟烷基取代的异恶唑化合物的方法

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1419788A (en) 1972-08-02 1975-12-31 Pfizer Herbicidal method using 2-trifuluromethyl-4-quinolinols
ATE161530T1 (de) 1992-09-04 1998-01-15 Takeda Chemical Industries Ltd Kondensierte heterozyklische verbindungen, deren herstellung und verwendung
ATE239797T1 (de) 1993-01-25 2003-05-15 Takeda Chemical Industries Ltd Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
ES2194937T3 (es) 1995-03-24 2003-12-01 Takeda Chemical Industries Ltd Compuestos ciclicos, su produccion y uso como antagonistas de los receptores de taquiquinina.
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
JP3816111B2 (ja) 1997-04-09 2006-08-30 インテレクト・ニューロサイエンシズ・インコーポレーテッド β−アミロイド末端に特異的な組換え抗体、それをコードするＤＮＡ及びその使用法
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
CA2322156A1 (en) 1998-03-03 1999-09-10 Ppg Industries Ohio, Inc. Impregnated glass fiber strands and products including the same
US20020132817A1 (en) 1998-03-19 2002-09-19 Hideaki Natsugari Heterocyclic compounds, their production and use
CA2352612A1 (en) 1998-11-27 2000-06-08 Hideo Fukui Pharmaceuticals
BRPI0108676B8 (pt) 2000-02-24 2021-05-25 Lilly Co Eli anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos
DE10045112A1 (de) 2000-09-11 2002-03-21 Merck Patent Gmbh Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
EP1335738A4 (en) 2000-11-03 2004-09-08 Proteotech Inc METHODS OF ISOLATING AMYLOID INHIBITOR COMPOUNDS AND USE OF COMPOUNDS USED FROM UNCARIA TOMENTOSA AND PARENT PLANTS
EP1432444A4 (en) 2001-08-17 2005-11-02 Lilly Co Eli ANTI-BETA ANTIBODIES
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
AU2003267098B2 (en) * 2002-09-11 2008-11-20 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors
EP1633786A4 (en) 2002-10-09 2007-07-25 Rinat Neuroscience Corp METHOD FOR TREATING ALZHEIMER DISEASE WITH ANTIBODIES TO AMYLOID BETA PEPTIDE AND COMPOSITIONS THEREOF
US20040157804A1 (en) 2002-10-16 2004-08-12 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
BRPI0410630A (pt) 2003-06-19 2006-06-13 Pfizer Prod Inc antagonista de nk1
WO2005025616A1 (ja) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited 抗体の用途
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
EP1718152A4 (en) * 2004-01-28 2009-09-16 Merck & Co Inc AMINOCYCLOPENTYL MODULATORS PYRIDOPYRAZINONE OF CHEMOKINE RECEPTOR ACTIVITY
BRPI0507374A (pt) 2004-02-02 2007-07-10 Pfizer Prod Inc moduladores do receptor de histamina-3
AU2005227258A1 (en) 2004-03-09 2005-10-06 Merck & Co., Inc. HIV integrase inhibitors
ES2315922T3 (es) 2004-04-14 2009-04-01 Gilead Sciences, Inc. Analogos de fosfonato de compuestos inhibidores de la integrasa del vih.
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
EP2298807A3 (en) 2004-07-30 2011-05-18 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
GB0423356D0 (en) 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents
FR2877015B1 (fr) 2004-10-21 2007-10-26 Commissariat Energie Atomique Revetement nanostructure et procede de revetement.
WO2006069081A2 (en) 2004-12-22 2006-06-29 Washington University In St. Louis USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
EP1881825B1 (en) 2005-05-10 2013-07-24 Merck Sharp & Dohme Corp. Hiv integrase inhibitors
NZ564187A (en) 2005-05-12 2010-03-26 Pfizer Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
WO2006126083A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
WO2006126081A2 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors
CA2608672A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
US7812040B2 (en) 2005-06-22 2010-10-12 Pfizer Inc. Histamine-3 receptor antagonists
TW200713011A (en) 2005-09-30 2007-04-01 Hon Hai Prec Ind Co Ltd System, method and electrical apparatus for data transferring
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
JP2009515997A (ja) 2005-11-18 2009-04-16 タケダ サン ディエゴ インコーポレイテッド グルコキナーゼ活性剤
US20070117839A1 (en) 2005-11-24 2007-05-24 Eisai R&D Management Co., Ltd. Two cyclic cinnamide compound
MY144960A (en) 2005-11-24 2011-11-30 Eisai R&D Man Co Ltd Morpholine type cinnamide compound
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
RU2448964C2 (ru) * 2006-01-20 2012-04-27 Шеринг Корпорейшн КАРБОЦИКЛИЧЕСКИЕ И ГЕТЕРОЦИКЛИЧЕСКИЕ АРИЛСУЛЬФОНЫ, ИХ ПРИМЕНЕНИЕ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, ОБЛАДАЮЩАЯ СВОЙСТВАМИ ИНГИБИТОРА γ-СЕКРЕТАЗЫ
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
US20090163482A1 (en) 2006-03-13 2009-06-25 Mchardy Stanton Furst Tetralines antagonists of the h-3 receptor
AU2007242555B2 (en) 2006-04-21 2010-12-16 Pfizer Products Inc. Pyridine[3,4-b]pyrazinones
WO2007136714A2 (en) 2006-05-16 2007-11-29 Gilead Sciences, Inc. Integrase inhibitors
CN101448793A (zh) 2006-05-19 2009-06-03 卫材R&D管理有限公司 脲型肉桂酰胺衍生物
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
PT2124933E (pt) 2007-01-22 2013-01-07 Pfizer Prod Inc Sal tosilato de um composto terapêutico e composições farmacêuticas do mesmo
JP2010518083A (ja) 2007-02-12 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション ピペリジン誘導体
AU2008215948A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of AD and related conditions
US20080207900A1 (en) 2007-02-28 2008-08-28 Teiji Kimura Two cyclic oxomorphorin derivatives
WO2008137102A2 (en) 2007-05-04 2008-11-13 Torreypines Therapeutics, Inc. Methods of modulating amyloid beta and compounds useful therefor
RU2009144998A (ru) 2007-05-07 2011-06-20 Шеринг Корпорейшн (US) Модуляторы гамма-секретазы
RU2009140182A (ru) 2007-05-11 2011-06-20 Ф. Хоффманн-Ля Рош Аг (Ch) Гетариланилины в качестве модуляторов для бета-амилоида
WO2008153792A2 (en) 2007-06-01 2008-12-18 Schering Corporation Gamma secretase modulators
WO2008153793A2 (en) 2007-06-01 2008-12-18 Schering Corporation Gamma secretase modulators
WO2008156580A1 (en) 2007-06-13 2008-12-24 Merck & Co., Inc. Triazole derivatives for treating alzheimer's disease and related conditions
US20110053918A1 (en) 2007-06-29 2011-03-03 Zhaoning Zhu Gamma secretase modulators
WO2009020580A1 (en) 2007-08-06 2009-02-12 Schering Corporation Gamma secretase modulators
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
EP2559693B1 (en) 2007-08-31 2014-11-26 Eisai R&D Management Co., Ltd. Polycyclic compound
WO2009032277A1 (en) 2007-09-06 2009-03-12 Schering Corporation Gamma secretase modulators
JP2010540524A (ja) 2007-09-28 2010-12-24 シェーリング コーポレイション ガンマセクレターゼモジュレーター
GB0720444D0 (en) 2007-10-18 2007-11-28 Glaxo Group Ltd Novel compounds
WO2009061699A1 (en) 2007-11-05 2009-05-14 Schering Corporation Gamma secretase modulators
JP2011506336A (ja) * 2007-12-06 2011-03-03 シェーリング コーポレイション γ−セクレターゼ調節剤
EP2227471A1 (en) 2007-12-11 2010-09-15 Schering Corporation Gamma secretase modulators
MX2010006379A (es) 2007-12-11 2010-09-07 Schering Corp Moduladores de la secretasa gamma.
WO2009075874A1 (en) 2007-12-13 2009-06-18 Amgen Inc. Gamma secretase modulators
BRPI0906799A2 (pt) 2008-01-11 2015-07-14 Hoffmann La Roche Moduladores para amiloide beta
JP5328816B2 (ja) 2008-02-22 2013-10-30 エフ．ホフマン−ラ ロシュ アーゲー アミロイドβの調節薬
US20100137320A1 (en) 2008-02-29 2010-06-03 Schering Corporation Gamma secretase modulators
JP2011513323A (ja) 2008-02-29 2011-04-28 シェーリング コーポレイション アルツハイマー病の治療のためのγ−セクレターゼモジュレーター
BRPI0912539A2 (pt) 2008-05-05 2015-10-13 Amgen Inc composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
TW201006801A (en) 2008-07-18 2010-02-16 Lilly Co Eli Imidazole carboxamides
WO2010019393A1 (en) 2008-08-13 2010-02-18 Merck Sharp & Dohme Corp. Pyrimidine derivatives for treatment of alzheimer's disease
EP2312945A4 (en) 2008-08-13 2012-05-09 Merck Sharp & Dohme PURE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER
RU2011111534A (ru) 2008-08-27 2012-10-10 ЭЙСАЙ Ар энд Ди МЕНЕДЖМЕНТ КО., ЛТД. (JP) Способ получения определенных цинниамидных соединений
MX2011003246A (es) 2008-10-09 2011-04-21 Hoffmann La Roche Moduladores de beta amiloide.
KR20110082189A (ko) 2008-11-06 2011-07-18 아스트라제네카 아베 아밀로이드 베타의 조절제
US20120129846A1 (en) 2008-11-06 2012-05-24 Zhaoning Zhu Gamma secretase modulators
JP2012508180A (ja) 2008-11-06 2012-04-05 シェーリング コーポレイション γ−セクレターゼ調節剤
WO2010052199A1 (en) 2008-11-10 2010-05-14 F. Hoffmann-La Roche Ag Heterocyclic gamma secretase modulators
WO2010071741A1 (en) 2008-12-16 2010-06-24 Merck Sharp & Dohme Corp. Triazole derivatives for treatment of alzheimer's disease
EP2379075A4 (en) 2008-12-16 2012-05-30 Merck Sharp & Dohme TRIAZOL DERIVATIVES FOR THE TREATMENT OF ALZHEIMER DISEASE
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
TW201034666A (en) 2008-12-22 2010-10-01 Schering Corp Gamma secretase modulators
AU2009330234A1 (en) 2008-12-22 2011-07-07 Merck Sharp & Dohme Corp. Gamma secretase modulators
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
NZ593951A (en) 2009-02-06 2013-01-25 Ortho Mcneil Janssen Pharm Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators
TWI461425B (zh) * 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
JP2012051807A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
JP2012051806A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
JP2012051805A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd テトラヒドロトリアゾロピリジン誘導体の製造方法
AU2010218667A1 (en) 2009-02-26 2011-07-21 Eisai R&D Management Co., Ltd. Salt of tetrahydrotriazolopyridine derivative and crystal thereof
JP2012121809A (ja) 2009-02-26 2012-06-28 Eisai R & D Management Co Ltd 多環式化合物の製造法およびその中間体
JP2012519682A (ja) 2009-03-03 2012-08-30 ファイザー・インク ガンマ−セクレターゼモジュレーターとしての新規フェニルイミダゾールおよびフェニルトリアゾール
AU2013261023B2 (en) 2012-05-16 2016-11-24 Cellzome Limited Substituted 3, 4 - dihydro - 2H - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) Alzheimer's disease
CN106413623B (zh) 2014-03-21 2020-07-03 阿莱恩技术有限公司 具有弹性体的分段的正畸矫正器

Also Published As

Publication number Publication date
EP2691393A1 (en) 2014-02-05
ES2602794T3 (es) 2017-02-22
JP5767393B2 (ja) 2015-08-19
WO2012131539A1 (en) 2012-10-04
US20120252758A1 (en) 2012-10-04
TW201300384A (zh) 2013-01-01
US20140045790A1 (en) 2014-02-13
US9067934B2 (en) 2015-06-30
US8697673B2 (en) 2014-04-15
CA2830027A1 (en) 2012-10-04
EP2691393B1 (en) 2016-09-14
JP2014510747A (ja) 2014-05-01
AR085748A1 (es) 2013-10-23
CA2830027C (en) 2016-04-26

Similar Documents

Publication Publication Date Title
UY33978A (es) Piridinonas bicíclicas nuevas.
UY34374A (es) Benzilindazoles sustituidos
UY34515A (es) Triazolopiridinas sustituidas
UY34559A (es) Inhibidores de bromodominios
UY33925A (es) Inhibidores tricíclicos de quinasas
UY34034A (es) Triazolopiridinas
UY34156A (es) Compuestos inhibidores de metaloenzimas
UY34765A (es) Compuestos novedosos.
UY34039A (es) Compuestos fungicidas
UY34006A (es) Imidazopiridazinas
UY33943A (es) Derivados espirocíclicos de isoxazolina como agentes antiparasitarios.
UY34302A (es) COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2- AMINA
UY4149Q (es) Golosina para mascota
UY34648A (es) Amidas como inhibidores de pim
UY34817A (es) Tienopirimidinas
UY34550A (es) Bencilpirazoles sustituidos
UY34503A (es) ?sal de bromhidrato de pridopidina?
UY4175Q (es) Reloj pulsera
UY34318A (es) ?derivados de isotiazolina útiles como compuestos insecticidas?
UY34329A (es) Compuestos de triazolopiridina
UY34253A (es) 3,4-dihidro-1h-[1,8]naftiridinonas antibacterianas sustituidas con ciclopenta[c]pirrol
UY33976A (es) Derivados de pirazolo-pirimidina.
UY4153Q (es) Batería
UY34791A (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2- dihidroquinolina-3-carboxamida
UY34043A (es) Isoxazolinas como agentes terapéuticos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201019